Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 46   

Articles published

ARNA 4.04 +0.07 (1.76%)
price chart
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Puts Another Treatment in the Pipeline
New drugs may make or break a pharmaceutical competitor, so Arena Pharmaceutical Inc (NASDAQ:ARNA, ARNA message board) announced an addition to its research and development pipeline, a new treatment for pulmonary arterial hypertension.
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Another recent example of a strong catalyst price moving event was when Arena Pharma (ARNA) saw its stock price rise from the low $2 range to over $3.50 a share before the ADCOM for its weight loss drug, Belviq, and a gap up in price from $3.66 to $7 ...
FDA Considers Faster Approval Process for Obesity Drugs
Arena Pharmaceuticals Inc.'s Belviq weight-loss pill and Vivus Inc.'s Qsymia may have been approved earlier for use by morbidly obese people had such a path existed.
Top Angel Investors of New England: An Innovation Slideshow
Investment Philosophy: "Invest in dynamic entrepreneurs in fields I like and understand. I look for some barriers to entry (IP), and if successful the potential for the company to be a large player. I try to stay away from small niche plays." ...
Vivus Pharmaceuticals (NASDAQ:VVUS) Falls on Readjusted Sales Expectations
The drug also comes out with a warning on cardio-vascular risks as the company has not completed the trials to prove safety. Competitor Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is just starting a post-market trial to assess heart and lung risk of the drug.
Eisai's Epilepsy Drug Reduces Weight in Obese Patients
The efficacy was similar to Roche Holding AG's Xenical and Arena Pharmaceuticals Inc.'s Belviq. Side effects such as mood changes and memory problems occurred more frequently than with a placebo, the authors of the study at Duke University Medical ...
Regulators scrutinize arcane realm of pet drug distribution
Drug company officials, antitrust lawyers, online pharmacy representatives, leaders with the American Veterinary Medical Association (AVMA) and a former Wal-Mart insider are among those who gathered to debate the issues.
More payers than expected cover Vivus' Qsymia
That could help the drug gain traction before its rival, Arena Pharmaceuticals' ($ARNA) Belviq, clears the Drug Enforcement Administration.
Survey Of The Obesity Drug Market
Also noteworthy is that the company has a dividend yield of 3.66%. Arena Pharmaceuticals: Belviq from Arena makes you lose appetite by affecting chemicals in your brain.
IPOs, FDA Approvals, and M&A Revive the Biotechnology Industry
... prostate cancer; Onyx Pharmaceuticals (NASDAQ:ONXX) for Kyprolis that treats a rare blood cancer; VIVUS Inc. (NASDAQ:VVUS) for Qsymia (TM) for the treatment of obesity; Arena Pharmaceuticals (NASDAQ:ARNA) for Lorcaserin that also treats obesity; ...